Analytical Data
-
Gene name
UGT1A4
- Application
-
Alternative Names
UGT1A4；GNT1；UGT1；UDP-glucuronosyltransferase 1A4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P22310
-
Expression Region
29-491aa
-
AA Sequence
GKVLVVPTDGSPWLSMREALRELHARGHQAVVLTPEVNMHIKEEKFFTLTAYAVPWTQKEFDRVTLGYTQGFFETEHLLKRYSRSMAIMNNVSLALHRCCVELLHNEALIRHLNATSFDVVLTDPVNLCGAVLAKYLSIPAVFFWRYIPCDLDFKGTQCPNPSSYIPKLLTTNSDHMTFLQRVKNMLYPLALSYICHTFSAPYASLASELFQREVSVVDLVSYASVWLFRGDFVMDYPRPIMPNMVFIGGINCANGKPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLD
-
Molecular Weight
59.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UGT1A4, or UDP-glucuronosyltransferase 1A4, is an essential enzyme in the metabolism of various endogenous and exogenous compounds, facilitating their elimination from the body through glucuronidation. This enzyme plays a critical role in drug metabolism, affecting pharmacokinetics and drug efficacy. Variations in the UGT1A4 gene can lead to differences in enzyme activity among individuals, which may influence responses to medications and susceptibility to drug interactions. Due to its significance in pharmacogenomics, the study of UGT1A4 has garnered attention in recent years, particularly in the context of personalized medicine. Research on recombinant UGT1A4 protein allows for a deeper understanding of its substrate specificity, kinetic properties, and the impact of genetic polymorphisms on its function. Utilizing recombinant DNA technology, scientists can produce UGT1A4 in vitro, enabling structured investigations into its enzymatic mechanisms and interactions with various drugs. Ultimately, insights gained from UGT1A4 studies could inform dosage recommendations and therapeutic strategies, enhancing patient outcomes in clinical settings. As drug discovery continues to evolve, understanding the characteristics of UGT1A4 is pivotal in addressing challenges associated with drug metabolism and individual variability in drug response.
